BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21159614)

  • 1. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
    Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
    Park EJ; Choi KS; Yoo YH; Kwon TK
    Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
    Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
    Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutlin-3 Promotes TRAIL-Induced Liver Cancer Cells Apoptosis by Activating p53 to Inhibit bcl-2 and Surviving Expression.
    Zhang C; Ni J; Fan W; Hou J
    Ann Clin Lab Sci; 2022 Jul; 52(4):601-610. PubMed ID: 36197780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
    Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
    Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
    Tseng HY; Chen LH; Ye Y; Tay KH; Jiang CC; Guo ST; Jin L; Hersey P; Zhang XD
    Carcinogenesis; 2012 Oct; 33(10):1871-81. PubMed ID: 22791814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Barbarotto E; Corallini F; Rimondi E; Fadda R; Mischiati C; Grill V; Vaccarezza M; Celeghini C
    J Cell Biochem; 2008 May; 104(2):595-605. PubMed ID: 18092340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
    Sarif Z; Tolksdorf B; Fechner H; Eberle J
    Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
    Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M
    J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
    Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
    Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
    Yoo J; Park SS; Lee YJ
    J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
    Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
    Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.